AstraZeneca plc, GlaxoSmithKline plc And The Future Of Pharma

Thinking of investing in AstraZeneca plc (LON: AZN) or GlaxoSmithKline (LON: GSK)? Then read this article.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The drugs industry used to be very simple. Companies would invest money in research to develop the next blockbuster drug. Patent protection would mean that these new drugs would provide a steady flow of income to Big Pharma. Much of the increased profit would then be spent on more research. And so we had the virtuous circle of increasing profits and increasing share prices that sustained the industry for years.

Big Pharma must be more creative

But about a decade ago, people started to realise that most of the low-hanging fruit had already been picked. In the 1980s stomach acid treatment Zantac was the best selling drug in the world. Around 2000, Losec was an even bigger seller. But nothing is ever linear. The follow-up medicines to these winners could simply not match their sales.

After all, if a doctor already has a treatment that cures the ailment without side effects, why should he or she spend more on a more recent drug that’s little different? That’s particularly so when the doctor is already familiar with the current medicine and it will soon be off-patent.

This means that Big Pharma is having to be far more creative about how it will generate its profits in coming years.

Today, there are still blockbuster drugs, but they’re biological rather than chemical medicines, based on antibody technologies that are now at the cutting edge of medical science. These treatments are providing step change improvements in diseases such as cancer and arthritis, and they’re a particular strength of AstraZeneca (LSE: AZN).

Adapt and survive

But most firms are finding that they have ageing pharmaceutical portfolios and many of their medicines will be branded and over-the-counter. Here profits will be generated by the quantity sold, rather than by margins. This is an approach that suits companies such as GlaxoSmithKline (LSE: GSK), with its broad portfolio of treatments.

And then there are emerging markets. This is where much of the growth will be as the ever-increasing middle classes of China, India and other emerging markets start to spend much more of their wealth on healthcare. The growing population of this world, and its increasing wealth, means that there will always be a market for the products that AstraZeneca and GlaxoSmithKline make. But we will see a shift in the mix, from the premium end to mass-market and budget treatments.

So the future of pharma is more complex than you might think. It’s no longer a linear game, but more a battle on many fronts. Medical research is advancing very fast. The pharmaceutical industry needs to adapt to advancing science, and a new, rapidly growing market with different priorities and different needs.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »